Palatin Technologies Inc (PTN)
1.19
-0.01
(-0.83%)
USD |
NYAM |
Nov 04, 16:00
1.15
-0.04
(-3.36%)
Pre-Market: 08:37
Palatin Technologies Research and Development Expense (Annual): 22.40M for June 30, 2024
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| June 30, 2024 | 22.40M |
| June 30, 2023 | 22.63M |
| June 30, 2022 | 21.33M |
| June 30, 2021 | 12.93M |
| June 30, 2020 | 13.96M |
| June 30, 2019 | 14.86M |
| June 30, 2018 | 32.57M |
| June 30, 2017 | 45.68M |
| June 30, 2016 | 43.07M |
| June 30, 2015 | 24.56M |
| June 30, 2014 | 10.83M |
| June 30, 2013 | 10.53M |
| June 30, 2012 | 13.81M |
| June 30, 2011 | 10.38M |
| June 30, 2010 | 12.29M |
| Date | Value |
|---|---|
| June 30, 2009 | 13.36M |
| June 30, 2008 | 21.19M |
| June 30, 2007 | 36.91M |
| June 30, 2006 | 41.01M |
| June 30, 2005 | 25.05M |
| June 30, 2004 | 23.33M |
| June 30, 2003 | 17.44M |
| June 30, 2002 | 12.12M |
| June 30, 2001 | 10.11M |
| June 30, 2000 | 9.110M |
| June 30, 1999 | 8.70M |
| June 30, 1998 | 7.10M |
| June 30, 1997 | 3.40M |
| June 30, 1996 | 0.8699M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
12.93M
Minimum
2021
22.63M
Maximum
2023
18.65M
Average
21.33M
Median
2022
Research and Development Expense (Annual) Benchmarks
| NovaBay Pharmaceuticals Inc | 0.068M |
| iBio Inc | 5.185M |
| Theriva Biologics Inc | 14.31M |
| Oragenics Inc | 15.49M |
| Nanoviricides Inc | 5.437M |